Seòmar agus comataidhean

The Scottish Government’s Chief Scientist Office (CSO) supports funding schemes for applied health research across the range of health challenges including prevention and treatment of infectious diseases. Applications are assessed through independent expert review with funding decisions based on the recommendations of independent expert research committees. Currently funded projects include an investigation of a novel class of antibiotic and on targeting antibiotic use.

In addition, CSO contributes financially to a range of National Institute for Health & Care Research funding schemes so these are open to applications from researchers in Scotland. These schemes can also consider applications for research relating to infectious diseases with funding recommendations made following independent expert review.

CSO also invests through NHS Research Scotland in a range of clinical research infrastructure to support Health Boards to host and participate in clinical studies and trials, including an Infectious Diseases Clinical Research Network to support the delivery of studies in this area.

The Scottish Government has also agreed, in principle, to join a new payment and evaluation model for new antimicrobial products, led by National Institute for Health & Care Excellence and NHS England. Frameworks are set to be finalised and in place by end of March 2023, at which point, all four nations will collectively decide on the new products that will be awarded contracts. If this new model is successful, we hope it will help to address supply chain issues by incentivising industry research and development into new antimicrobials.

The Scottish Government continues to focus on tackling disparities in deprived areas by ensuring equitable access to cancer services through the actions in our National Cancer Plan. We recognise that the impact from the COVID-19 pandemic may have exacerbated inequalities within screening. A key Ministerial priority is reducing inequalities in access to and uptake of screening programmes. That is why we committed up to £2.45 million to the Screening Inequalities Fund to build a programme of evidence-based, sustainable and scalable projects that tackle inequalities in a systemic way.

Rapid Cancer Diagnostic Services (RCDS) have been established across three NHS Boards to date which have a key role in delivering earlier diagnosis and improving patient care. The First Minister recently announced an additional two RCDS’ are being developed.

Additionally, the development of national clinical management pathways through the Scottish Cancer Network will help reduce variation across Scotland, across the entirety of the pathway. In parallel, the first optimal cancer diagnostic pathway, led by the Centre for Sustainable Delivery (CfSD) was launched in December 2022, and is being funded by £3 million from the Scottish Government’s Detect Cancer Earlier (DCE) Programme.

As committed to in the National Workforce Strategy for Health and Social Care, we have been undertaking a data collection exercise to inform future decisions about workforce investment. This work is being led by the Scottish Cancer Network, which is engaging with local boards and professional representatives.

A final report, including recommendations, will be provided to the National Oncology Taskforce in the first quarter of 2023. The Taskforce is made up of NHS Board Chief Executives and Medical Directors, and will seek national solutions to ensure the longer term resilience of oncology services in Scotland.

In November 2022, Public Health Scotland published a report analysing the 2022 survey of the General Practice workforce. This publication is available at General practice workforce survey 2022 - General practice workforce survey - Publications - Public Health Scotland . Following this work in 2022, the Scottish Government has committed to undertaking the workforce survey on an annual basis.

There are regular meetings between Scottish Government officials and the Medicines and Healthcare products Regulatory Agency (MHRA) representatives, covering a wide range of subjects. The last such meeting took place on 10 January 2023 when the MHRA Cross-UK Partnership group met. The purpose of the MHRA Cross-UK Partnership group is to ensure that officials from the devolved administrations are kept updated on key MHRA issues that may affect or involve them. At the last meeting, the MHRA Corporate Plan, its Post Implementation Review of the Human Medicines Regulations, and safety issues were discussed.

The Chief Pharmaceutical Officer is a member of the Sodium Valproate Implementation Working Group, which is supporting the safe introduction of new measures to further strengthen the safe prescribing of sodium valproate in clinical practice. The group last met on 6 January 2023.

A meeting took place on 9 December 2022 with the Chief Medical Officers and the Deputy Chief Medical Officers and the MHRA Chief Executive was invited as a guest. Dame June Raine attended briefly on 9 December and provided an informal update on sodium valproate.

I refer the member to the Neurological Care And Support: A Framework For Action 2020-2025 – Midpoint Progress Report , which was published on 13 July 2022. This report provides an update on the progress under each of the five aims in the Neurological Care And Support: A Framework For Action 2020-2025.

Specifically, page 13 of the report details a project we funded to develop principles of good transition across the lifespan of people with neurological conditions, using a range of methodologies.

More widely, Scottish Government will introduce Scotland’s first National Transitions to Adulthood Strategy in this Parliamentary term to ensure there is a joined-up approach to supporting our young people with disabilities as they make the transition to adult life. The scope of the Strategy will be developed through engagement with people with lived experience of transitions in all areas of life, including health care. We will begin progressing external engagement on the Strategy in early 2023.

In 2019, we published a Neurological Care and Support – a National Framework for Action 2020-25 , with a vision to ensure everyone with a neurological condition can access the care and support they need to live well, on their own terms.

The aims include improving the provision of co-ordinated health and social care and support, developing sustainable workforce models and ensuring high standards of person-centred care.

Despite the disruption to health and social care services during the pandemic, we have sustained our efforts to deliver the 17 commitments of the Framework. Since October 2020 we have we have awarded £2.1 million to fund innovative projects by NHS Boards, Health and Social Care Partnerships and third sector organisations working to achieve better outcomes for people living with neurological conditions.

I further refer the member to the Neurological Care And Support: A Framework For Action 2020-2025 – Midpoint Progress Report , which was published on 13 July 2022. This report provides an update on the progress under each of the five aims in the Neurological Care And Support: A Framework For Action 2020-2025.

In 2021 we supported the Neurological Alliance of Scotland (NAoS) to produce three new ‘What to Expect’ information guides for carers of people with neurological conditions. These guides include information on carers’ rights under the Carers (Scotland) Act 2016 and comprise:

• What to expect when you are new to caring
• What to expect from advocacy services
• What to expect when planning ahead

The guides were endorsed by the Coalition of Carers and are available at the NAoS website: https://www.scottishneurological.org.uk

We are currently supporting the NAoS to undertake a project in early 2023 to work with carers centres assessing current resources and identifying gaps that still need to be addressed regarding information, training and signposting.

Through the Neurological Care and Support – a National Framework for Action 2020-25 , Scottish Government and the Centre for Sustainable Delivery (CfSD) are improving referral pathways. The CfSD continues to work with neurological services to support the appropriate adoption of Active Clinical Referral Triage (ACRT) which ensures patients receive the right care in an appropriate setting, and Patient Initiated Review (PIR) which puts patients at the centre of their care.

The CfSD is working with Public Health Scotland towards capturing data in relation to ACRT and Discharge PIR, which will provide a better understanding of the scale, spread and potential further opportunity of these approaches.

The CfSD Neurology Specialty Delivery Group are developing a number of GP fact sheets for common neurological symptoms designed to support clinical triage by ensuring patients access the correct pathways in timely, robust and appropriate manner. These resources are intended to support good communication between secondary and primary care. They have been developed by a multi-Board expert group of primary and secondary care clinicians and are currently being prepared for national use.

Through our Neurological Care and Support – a National Framework for Action 2020-25 we are also funding condition-specific pathway work, in particular regarding Functional Neurological Disorder and migraine.

I refer the member to the answer to question S6W-13707 on 23 January 2023. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers